The American Heart Association has developed an updated strategy for the prevention and management of cardiovascular disease. A newly defined health condition, cardiovascular-kidney-metabolic syndrome, sits at the center of that strategy. 

“Given the dramatic difference in death risk for older adults receiving complex PCI, we suggest that such interventions in this exceptionally vulnerable population should be approached with additional caution," researchers wrote. 

The two anticoagulants are associated with similar mortality rates. However, a new meta-analysis in Circulation may have cardiologists favoring bivalirudin over heparin. 

According to a new analysis of more than 280,000 deaths, the number of obesity-related cardiovascular deaths in the United States tripled from 1999 to 2020. 

Researchers uncovered new details about how mitral regurgitation can impact one-year TAVR outcomes, sharing their findings in the Journal of the American Heart Association.

Both conditions are fairly common in patients who undergo TAVR. Is this something cardiologists should be keeping in mind? 

The updated recommendations from the American College of Cardiology and American Heart Association cover a variety of topics, including patient communication, follow-up imaging, nutritional supplements and more. 

The new AUC document, which examines the treatment of both symptomatic and asymptomatic patients, was published in full in the Journal of the American College of Cardiology.